Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CX501 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| CX501 | EXPERIMENTAL | Cultured chimeric skin |
| Non adherent dressing | ACTIVE_COMPARATOR | Occlusive non adherent dressing |
| Name | Type | Description |
|---|---|---|
| CX501 | DRUG | Cultured chimeric skin |
| Occlusive non adherent dressing | DEVICE | Application of an occlusive non adherent dressing in the skin donor site |
Inclusion criteria: * Patients of both sexes over 28 days of age. * Patients with recessive dystrophic epidermolysis bullosa diagnosed by clinical and historical criteria with severe skin syndactyly in whom reconstructive surgery is indicated. * Patients whose legal guardians have given written inf...
CX501 is being developed for the treatment of epidermolysis bullosa, a rare genetic skin condition. It is a small molecule therapeutic candidate that Takeda Pharmaceutical Company Limited has studied in a Phase 2 clinical trial. The program targets a rare disease indication with high unmet medical need.
CX501 is being developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. Takeda is the sponsor behind the clinical program evaluating CX501 in epidermolysis bullosa. The company is a global pharmaceutical developer with a portfolio spanning multiple therapeutic areas, including rare diseases.
CX501 has completed a Phase 2 clinical trial in epidermolysis bullosa. It is an investigational therapy and is not approved for commercial use. The Phase 2 study has finished, and no active trials of CX501 are currently listed. Further development steps would depend on Takeda's program decisions.
CX501 was evaluated in a single Phase 2 trial, NCT00987142, titled a trial to assess efficacy of a chimeric skin in patients with epidermolysis bullosa. The study enrolled 12 participants in Spain, included patients from 28 days of age, and used an active-controlled design. It is listed as completed.
The CX501 Phase 2 trial, NCT00987142, was an active-controlled study that enrolled 12 patients with epidermolysis bullosa. It was not randomized and not double-blind, and it did not use biomarker selection. Participants were recruited in Spain, and the trial included both male and female patients starting at 28 days of age.